Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àç¹ß¼º ȤÀº ÁøÇ༺ Á÷Àå¾Ï¿¡ ´ëÇÑ °ñ¹Ý³»ÀåÀûÃâ¼ú(Pelvic Exenteration)ÀÇ ÀÓ»óÀû °æÇè Pelvic Exenteration as the Treatment for Recurrent or Locally Advanced Rectal Cancer

´ëÇÑ´ëÀåÇ×¹®ÇÐȸÁö 2005³â 21±Ç 5È£ p.314 ~ 319
¼Û½Â±Ô, ¹Ú¿ë±Ù, ¼­±¤¿í,
¼Ò¼Ó »ó¼¼Á¤º¸
¼Û½Â±Ô ( Song Seung-Kyu ) 
¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

¹Ú¿ë±Ù ( Park Yong-Keun ) 
¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
¼­±¤¿í ( Suh Kwang-Wook ) 
¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

Abstract


Purpose: The purpose of this study is to evaluate the value of pelvic exenteration (PE) for recurrent or locally advanced rectal cancer.

Methods: This retrospective study analyzed 20 patients who underwent PE for rectal cancer from June 1994 to October 2003 in Ajou University Hospital. The surgical severity, the postoperative complications, and the survival rate were analyed based on the medical records.

Results: The mean operation time was 221.5⁑93.0 minutes, the mean blood loss 750.5⁑223.3 cc, and the mean transfusion amount RBC 6.5⁑4.3 units. Operative mortality was 5% (1/20). A bleeding-associated complication was noted in one patient who underwent a reoperation for hemostasis. Other minor complications were small bowel obstruction (n=3), abdominal wound infection (n=5), vesicocutaneous fistula (n=2), delayed healing of the perineal wound (n=10). The overall 5-year survival rate was 52.6% (10 of 19 patients, excluding the operative mortality case).

Conclusions: Our study showed acceptable surgical severity and postoperative complications and a favorable 5-year survival rate (¡Ý50%) for pelvic exenteration as a treatment for recurrent or locally advanced rectal cancer. With strictly selected patients, PE may be one of the treatment options for recurrent or locally advanced rectal cancer. J Korean Soc Coloproctol 2005;21:314- 319

Å°¿öµå

±¹¼Ò ÁøÇ༺ Á÷Àå¾Ï;Àç¹ß¼º Á÷Àå¾Ï;°ñ¹Ý³»ÀåÀûÃâ¼ú
Locally advanced rectal cancer;Recurrent rectal cancer;Pelvic exenteration

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS